Patents Assigned to APOLLO LIFE SCIENCES LIMITED
-
Publication number: 20090311247Abstract: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule such as EPO, Flt3-Ligand, Flt3, PDGF-B or VEGF-165 or chimeric molecules thereof comprising at least a portion of the protein molecule, wherein the protein or chimeric molecule has a profile of measurable physiochemical parameters which is indicative of, associated with or forms the basis of, one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.Type: ApplicationFiled: November 18, 2005Publication date: December 17, 2009Applicant: APOLLO LIFE SCIENCES LIMITEDInventors: John D. Priest, Alan D. Watts, Jason S. Whittaker, Teresa A. Domagala, Raina J. Simpson, Glenn R. Pilkington, Catherine A. Liddell, Ingrid Boehm, Carol M. Y. Lee
-
Publication number: 20090232808Abstract: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule in or related to the tumour necrosis factor (TNF) superfamily such as TNF-a, Lymphotoxin-a (LT-a), TNFRI, TNFRII, OX40, BAFF, NGFR, Fas Ligand or chimeric molecules thereof comprising at least a portion of the protein molecule, such as TNF-a-Fc, LT-a-Fc, TNFRI-Fc, TNFRII-Fc, OX40-Fc, BAFF-Fc, NGFR-Fc, Fas Ligand-Fc; wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.Type: ApplicationFiled: January 27, 2006Publication date: September 17, 2009Applicant: APOLLO LIFE SCIENCES LIMITEDInventors: John D. Priest, Alan D. Watts, Jason S. Whittaker, Teresa A. Domagala, Glenn R. Pilkington, Ingrid Boehm, Carol M. Y. Lee, Mei Ann Lim, Nikolien S. Thomas
-
Publication number: 20090202472Abstract: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule in or related to the IL-2 protein family such as IL-2, IL-2Ra, IL-2Rb, IL-2Rg or chimeric molecules thereof, such as IL-2-Fc, IL-2Ra-Fc, IL-2Rb-Fc and IL2Rg-Fc, comprising at least a portion of the protein molecule; wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.Type: ApplicationFiled: November 24, 2005Publication date: August 13, 2009Applicant: APOLLO LIFE SCIENCES LIMITEDInventors: John D. Priest, Alan D. Watts, Jason S. Whittaker, Glenn R. Pilkington, Catherine A. Liddell
-
Publication number: 20090175819Abstract: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule that comprises a dimeric 4-helix bundle, such as IFN-a2B, IFN-b1, IFN-g, IL-10 or its receptor, such as IFNAR2, IL-10Ra or chimeric molecules thereof comprising at least a portion of the protein molecule, such as IFN-a2B-Fc, IFN-b1-Fc, IFN-g-Fc, IFNAR2-Fc, IL-IO-Fc, IL-10Ra-Fc; wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.Type: ApplicationFiled: February 14, 2006Publication date: July 9, 2009Applicant: APOLLO LIFE SCIENCES LIMITEDInventors: John D. Priest, Alan D. Watts, Jason S. Whittaker, Teresa A. Domagala, Carol M. Y. Lee, Raina J. Simpson, Ingrid Boehm, Stuart Jackson, Catherine A. Liddell, Glenn R. Pilkington, Melissa Corbett
-
Publication number: 20090155267Abstract: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule which comprises a C-type lectin or an EGF-like domain such as amphiregulin, CD209L, Langerin, L-selectin or chimeric molecules thereof comprising at least a portion of the protein molecule, such as amphiregulin-Fc, CD209L-Fc, Langerin S, Langerin L, Langerin L-FLAG, Langerin-Fc, L-selectin-Fc wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.Type: ApplicationFiled: February 9, 2006Publication date: June 18, 2009Applicant: APOLLO LIFE SCIENCES LIMITEDInventors: John D. Priest, Alan D. Watts, Jason S. Whittaker, Teresa A. Domagala, Carol M. Y. Lee, Nikolien S. Thomas
-
Publication number: 20090142294Abstract: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule in or related to the short chain 4 helix bundle superfamily such as GM-CSF, IL-3, IL-4 and IL-5 or chimeric molecules thereof comprising at least a portion of the protein molecule, such as GM-CSF-Fc, IL-3-Fc, IL-4-Fc and IL-5-Fc; wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.Type: ApplicationFiled: January 25, 2006Publication date: June 4, 2009Applicant: APOLLO LIFE SCIENCES LIMITEDInventors: John D. Priest, Alan D. Watts, Jason S. Whittaker, Glenn R. Pilkington, Catherine A. Liddell, Ingrid Boehm
-
Publication number: 20090136444Abstract: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule in or related to the IL-6 protein family such as G-CSF, IL-11, IL-6, LIF or chimeric molecules thereof, comprising at least a portion of the protein molecule; wherein the protein or chimeric molecule thereof has a profile of measurable physiochemical parameters, wherein the profile is indicative of, associated with or forms the basis of one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and/or research applications.Type: ApplicationFiled: November 11, 2005Publication date: May 28, 2009Applicant: APOLLO LIFE SCIENCES LIMITEDInventors: John D. Priest, Alan D. Watts, Jason S. Whittaker, Stuart Jackson, Teresa A. Domagala, Raina J. Simpson, Glenn R. Pilkington, Catherine A. Liddell
-
Publication number: 20070269436Abstract: The present invention relates to a method for the in vitro production of antibody in an antigen specific manner and, more particularly, to the in vitro production of human antibody in an antigen specific manner. The present invention further extends to the antibody produced therefrom and to the antibody producing cells produced in accordance with the methods disclosed herein. The antibodies and antibody producing cells of the present invention are useful, inter alia, in a range of therapeutic, prophylactic and diagnostic applications.Type: ApplicationFiled: December 10, 2003Publication date: November 22, 2007Applicant: Apollo Life Science LimitedInventor: Jianhe Chen
-
Publication number: 20070243132Abstract: The present invention generally relates to a vehicle useful for delivering a pharmaceutically active compound including a genetic molecule or composition. More particularly, the present invention provides microemulsions for transdermal delivery of pharmaceutically active agents to a subject.Type: ApplicationFiled: December 22, 2006Publication date: October 18, 2007Applicant: Apollo Life Sciences LimitedInventors: Gregory Russell-Jones, Michael Luke, Stewart Himes